Eserler a. Uluslararası hakemli dergilerde yayımlanan makaleler: sadik, S., Onoglu, as., M. M. Inal



Download 248.43 Kb.
Page2/3
Date08.05.2017
Size248.43 Kb.
1   2   3


L5. (A19). M.M. Inal, Yildirim, Y., Taner, CE., “Comparison of the Clinical Efficacy of Flutamide and Spironolactone plus Diane 35 in the Treatment of Idiopathic Hirsutism: A Randomized Controlled Study”, Fertil Steril, 84 (6): 1693-1697 (2005).

L5.1. Martin, KA., Chang, RJ., Ehrmann, DA., Ibanez, L., et al. “Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline”, The Journal of Clinical Endocrinology & Metabolism, 93 (4): 1105-1120 (2008).

L5.2. Blume-Peytavi, U., Hahn, S., “Medical treatment of hirsutism”, Dermatologic Therapy, 21 (5): 329–339 (2008).

L5.3. Radosh, L., “Drug Treatments for Polycystic Ovary Syndrome”, American Family Physician, 79 (8): (2009).

L5.4. Karakurt, F., Sahin, I., Güler, S., Demirbas, B., Culha, C., Serter, R., Aral, Y., Bavbek, N., “Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: A randomised controlled study”, Advances in Therapy, 25 (4): 321-328 (2008).

L5.5. Al Robaee, A., Al-Zolibani, A., Al-Shobaili, HA., Aslam, M., “Update on hirsutism”, Acta Dermatoven APA, 17 (3): 103-119 (2008).

L5.6. Branco, CC., Cancelo, MJ., “Comprehensive clinical management of hirsutism”, Gynecological Endocrinology, 26 (7): 484-493 (2010).

L5.7. Maharaj, S., Amod, A., “Polycystic ovary syndrome”, Journal of Endocrinology, Metabolism and Diabetes of South Africa, 14 (2): 86-95 (2009).

L5.8. Pizzo, A., Borrielli, I., Raffone, E., Vaiarelli, A., Stella, NC., “The interference of the flutamide on the sexual differentiation of a male fetüs. A case report”, Giornale italiano di ostetricia e ginecologia, 31 (8/9): 363-365 (2009).

L5.9. Kriplani, A., Thulkar, J., Agrawal, N., Kulshrestha, V., et al, “A Comparative Study of Diane‐35 plus spironolactone and Diane ‐35 Plus Finasteride in Cases of Hirsutism and Acne”, Int J Endocrinol Metab, 7 (4): 235-241 (2009).

L5.10. Lakshmi, C., “Hormone therapy in acne”, Indian J Dermatol Venereol Leprol, 79 (3): 322-37 (2013).

L5.11. Jiang-yuan, L., “Idiopathic hirsutism and its diagnosis and treatment”, Chinese Journal of practical internal medicine, 27 (23): (2007).

L5.12. Palacios, A., “Advances in the diagnosis and treatment of hirsutism in adolescent and young adult”, Revista Venezolana de Endocrinología y Metabolismo, 6 (1): 35-38 (2009).

L5.13. Blume-Peytavi, U., “How to diagnose and treat medically women with excessive hair”, Dermatologic Clinics, 31 (1): 57-65 (2013).

L5.14. Caswell, AH., “Evolutionary Basis of Homosexuality – a Hypothesis of Socio-sexual Interaction”, (2011).

L5.15. Czernichow, PRP., “GH treatment of non growth hormone deficient short stature”, Rev. Venez. Endocrinol. Metab, 6 (1): 27-29 (2008).

L5.16. Pugeat, M., Kaddar, N., Raverot, V., “Recommended Treatment Modalities for Hyperandrogenism”, Polycystic Ovary Syndrome: Contemporary Endocrinology pp 295-306 (2008).

L5.17. Metwally, M., “Hirsutism”, Obstetrics, Gynaecology & Reproductive Medicine, 22 (8): 211–214 (2012).

L5.18. Hernandez-Escareno, A., "Comparing The Hormone, Metabolic, And Lipid Profiles Of Reproductive Age Women And The Effects Of Dried Apple Supplementation And Resistance Exercise In Women With Polycystic Ovary Syndrome", Florida State University, Electronic Theses, Treatises and Dissertations. Paper 4086 (2009).

L5.19. Lumachi, F., Zulian, E., Scaroni, C., “Cost-effective Therapy in Patients with Idiopathic Hirsutism”, Expert Review of Pharmacoeconomics and Outcomes Research, 4 (3): 297-306 (2004).

L5.20. Sahin, Y., Kelestimur, F., “Medical Treatment Regimens of Hirsutism”, Reproductive BioMedicine Online, 8 (5): 538-546 (2004).

L5.21. Reismann, P., Liko, I., Patocs, A., “Pharmacological options for treatment of hyperandrogenic disorders”, Mini Reviews in Medicinal Chemistry, 9: (9): 1113-1126 (2009).

L5.22. 2013 Compendium of Clinical Practice Guidelines; Evaluation and Treatment of Hirsutism in Premenopausal Women, DOI: http://dx.doi.org/10.1210/CCPG.9781936704668.ch20; Published Online: November 20, 2013.

L6 (A16). Yildirim, Y., M.M. Inal, Sanci, M., Yildirim, YK., Mit, T., Polat, M., Tinar, S., “Development of Uterine Sarcoma after Tamoxifen Treatment for Breast Cancer: Report of Four Cases”, Int J Gynecol Cancer, 15 (6): 1239-1242 (2005).

L6.1. Moinfar, F., Azodi, M., Tavassoli, FA., “Uterine sarcomas”, Pathology, 39 (1): 55-71 (2007).

L6.2. Huang, GS., Gunter, MJ., Arend, RC., Li, M., Arias-Pulido, H., Prossnitz, ER., Goldberg, GL., Smith, HO., “Co-expression of GPR30 and ERβ and their association with disease progression in uterine carcinosarcoma”, American Journal of Obstetrics & Gynecology, 203 (3): 242.e1 -242.e5 (2010).

L6.3. Lavie, O., Barnett-Griness, O., Narod, SA., Rennert, G., “The risk of developing uterine sarcoma after tamoxifen use. International Journal of Gynecological Cancer, 18 (2): 352–356 (2008).

L6.4. Teo, SY., Babagbemi, KT., Peters, HE., Mortele, KJ., “Primary Malignant Mixed Müllerian Tumor of the Uterus: Findings on Sonography, CT, and Gadolinium-Enhanced MRI”, American Journal of Roentgenology, 191 (1): 278-283 (2008).

L6.5. Harry, VN., Narayansingh, GV., Parkin, DE., “Uterine leiomyosarcomas: a review of the diagnostic and therapeutic pitfalls”, The Obstetrician & Gynaecologist, 9 (2): 88–94 (2007).

L6.6. Gottwald, L., Gora, E., Korczynski, J., Piekarski, JH., Morawiec, Z., Jesionek-Kupnicka, D., Sowa, P., Cialkowska-Rysz, A., Bienkiewicz, A., “Primary uterine rhabdomyosarcoma in a patient with a history of breast cancer and gastrointestinal stromal tumor”, Journal of Obstetrics and Gynaecology Research, 34 (4): 721–725 (2008).

L6.7. Suprasert, P., Khunamornpong, S., “Carcinosarcoma arising in uterine didelphys after tamoxifen therapy for breast cancer: a case report”, J Med Assoc Thai, 93 (5): 608-12 (2010).

L6.8. Buccoliero, AM., Fambrini, M., Gheri, CF., Castiglione, F., Garbini, F., Barbetti, A., et al. “Surveillance for Endometrial Cancer in Women on Tamoxifen: The Role of Liquid-Based Endometrial Cytology – Cytohistological Correlation in a Population of 168 Women”, Gynecol Obstet Invest, 65 (4): 240–246 (2008).

L6.9. Saim, M., Cote, JF., Morel, O., Malartic, C., Akerman, G., Gray, F., Barranger, E., “Malignant mixed müllerian tumor of the uterus following tamoxifen for breast cancer: Case report”, Gynécologie Obstétrique & Fertilité, 36 (2): 166–168 (2008).

L6.10. Homer, L., Muller, M., Dupre, PF., Lucas, B., Pradier, O., “Uterine sarcoma associated with tamoxifen use after breast cancer: Review of the pathogenesis”, Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 38 (8): 629–633 (2009).

L6.11. Brennan, MF., Antonescu, CR., Maki, RG., “Leiomyosarcoma”, Management of Soft Tissue Sarcoma, p.113-127 (2013).

L6.12. Yıldırım, Y., Toz, E., “The Effect of Long-Term Tamoxifen Usage on the Lower Part of Female Genital Tract in Breast Cancer Survivors: A Review”, Marmara Medical Journal, 20 (3): 196-201 (2007).

L6.13. Xiaonan, Z., Jingliang, C., Feifei, W., Mengtian YS., “One case: malignant mixed Mullerian tumor of the uterus”, Practical Journal of Radiology, 29 (8): (2013).

L6.14. van Meurs, HS., Dieles, JJ., Stel, HV., “A uterine leiomyoma in which a leiomyosarcoma with osteoclast-like giant cells and a metastasis of a ductal breast carcinoma are present”, Annals of Diagnostic Pathology, 16 (1): 67–70 (2012).

L6.15. Vasconcelos, ALC., Nunes, B., Duarte, C., Mendonca, V., Ribeiro, J., Jorge, M., Grillo, IM., “Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma—A report of 8 cases and review of the literature”, Reports of Practical Oncology & Radiotherapy, 18 (5): 251–260 (2013).

L6.16. Caramelo, O., Marinho, C., Rebelo, T., et al., “A Case of Endometrial Stromal Sarcoma with Synchronous Bilateral Adenocarcinoma of Ovary,” Case Reports in Obstetrics and Gynecology, 2012: 1-5 (2012).

L6.17. Koukouliata, A., “Malignant mixed mullerian tumor in two patients receiving tamoxifen therapy”, Prog Health Sci, 1 (1): 167-170 (2011).

L6.18. Barry, L., Baxter, G., Pitchamuthu, H., Crooks, JE., Rajan, P., Ahmad, I., “Aggressive bladder leiomyosarcoma in a patient receiving tamoxifen therapy”, Journal of Clinical Urology, 6: 327-329 (2013).

L6.19. Shor, AC., "Src kinase inhibitors for the treatment of sarcomas: Cellular and molecular mechanisms of action", Graduate School Theses and Dissertations, University of South Florida (2007).

L7 (A27). Onay H., Ugurlu T., Aykut A., Pehlivan S., M. Inal, Tinar S., Ozkinay C., Ozkinay F., “Rapid prenatal diagnosis of common aneuploidies in amniotic fluid using quantitative fluorescent polymerase chain reaction”, Gynecol Obstet Invest, 66 (2): 104-10 (2008).

L7.1. Cirigliano, V., Voglino, G., Ordoñez, E., Marongiu, A., Paz Cañadas, M., Ejarque, M., Rueda, L., Lloveras, E., Fuster, C., Adinolfi, M., “Rapid prenatal diagnosis of common chromosome aneuploidies by QF-PCR, results of 9 years of clinical experience, Prenat. Diagn, 29 (1): 40–49 (2009).

L7.2. Faas, BHW., Cirigliano, V., Bui, TH., “Rapid methods for targeted prenatal diagnosis of common chromosome aneuploidies”, Seminars in Fetal & Neonatal Medicine, 16 (2): 81-87 (2011).

L7.3. Yan,C., Yu-ning,Z., Shi-ming,L., Jian-fei,Y., Yu, M., “Establishment and Application of 18-STR Database in Han Population from Zhejiang Province”, J SUN Yat-sen Univ (Med Sci)31 (1)122-128 (2010).

L7.4. Langlois, S., Duncan, A., “Use of a DNA method, QF-PCR, in the prenatal diagnosis of fetal aneuploidies”, J Obstet Gynaecol Can, 33 (9): 955-60 (2011).

L7.5. Rivkees, SA., Hager, K., Hosono, S., Wise, A., Li, P., Rinder, HM., Gruen, JR., “A Highly Sensitive, High-Throughput Assay for the Detection of Turner Syndrome”, The Journal of Clinical Endocrinology & Metabolism, 96 (3): (2011).

L7.6. Yan-Ping, L., Jing C., Shu-Fang, J., Zhang, L., Zhi-Ying, G., et al. “Development of Multiple Quantitative Fluorescent PCR for Rapid Diagnosis of Common Aneuploidy and It's Clinical Application”, Heredity, 11 (32): 1141-1146 (2010).

L7.7. Xiangyu, Z., Yali, H., “Advances in diagnosis of fetal chromosomal abnormalities methods”, Chinese Journal of perinatal medicine, 12 (2): (2009).

L7.8. Allingham-Hawkins, DJ., Chitayat, D., Cirigliano, V., Summers, A., Tokunaga, J., Winsor, E., Chun, K., “Prospective validation of quantitative fluorescent polymerase chain reaction for rapid detection of common aneuploidies”, Genetics in Medicine, 13 (2): 140–147 (2011).

L7.9. Ai-qun, X., Xu-ming, B., Jun-tao, L., Feng-xia, Y., Wei-min, Z., Na, H., Jing, Z., “Establishment of multiple quantitative fluorescent polymerase chain reaction assay and its application in rapid prenatal diagnosis of common chromosome aneuploidies”, Chinese Journal of obstetrics and Gynecology, 45 (7): (2010).

L7.10. Atef, SH., Hafez, SS., Mahmoud, NH., Helmy, SM., “Prenatal diagnosis of fetal aneuploidies using QF-PCR: the egyptian study”, J Prenat Med, 5 (4): 83–89 (2011).

L7.11. Manlong, Q., Yuanyuan, Z., Harpole, LX., Zhao, Y., “QF-PCR in the diagnosis of chromosomal abnormality in male infertility”, Genetic, 8: (2011).

L7.12. Scott, P., Podemski, L., Wyatt, KB., Walker, C., et al. “Toward Optimal Detection of the Common Prenatal Aneuploidies by Quantitative Fluorescent–Polymerase Chain Reaction: Comparison of Two Commercial Assays”, Genetic Testing and Molecular Biomarkers, 16 (8): 943-947 (2012).

L7.13. Ozturk, E., Ugur, MG., Cebesoy, FB., Aydın, A., Sever, T., Balat, O., “Good prognosis for primary ovarian pure nongestational choriocarcinoma using the EMA/CO regime”, Eur. J. Gynaec. Oncol, 31 (1): 123-125 (2010).

L7.14. Wei, J., Lei, F., “Human short tandem repeat sequence correlation technique and its application in forensic science progress”, Chinese Journal of New Clinical Medicine, 11: (2011).

L7.15. Dikensoy, E., Balat, O., Pehlivan, S., Cebesoy, FB, Kutlar, AI., Sever, T., Baltacı, V., “A false negative QF-PCR and Trisomy 18-Trisomy 9 mosaicism”, J Turk Soc Obstet Gynecol, 8 (1): 67- 70 (2011).

L7.16. Helmy, SMH., Essawi, M., Bassiouni, R., Gaber, KR., “Rapid PNCD for Common Aneuploidies Uusing QF-PCR in Egyptian Women”, Research Journal of Medicine and Medical Sciences, 4 (2): 446-451 (2009).

L7.17. Furtado, LV., Jama, MA, Paxton, CN., Wilson, AA., Gardiner, AE., Lyon, E., Geiersbach, KB., “Aneuploidy Detection in Paraffin Embedded Tissue from Products of Conception by Mini-STR Genotyping”, Fetal & Pediatric Pathology, 32 (2): 133-150 (2013).

L7.18. Güngör, ANÇ., Hacıvelioğlu, S., Uludağ, A., Gencer, M., et al “Fetal Anöploidi Açısından Yüksek Riskli Gebeliklerin QF-PCR İle Analizi”, International Journal of Clinical Research, 1 (1): 17-21 (2013).

L8 (A8). M.M. Inal, Hanhan, M., Pilanci, B., Tinar, S., “Fallopian Tube Malignancies: Experience of Social Security Agency Aegean Maternity Hospital”, Int J Gynecol Cancer, 14 (4): 595-599, (2004).

L8.1. Pectasides, D., Pectasides, E., Economopoulos, T., “Fallopian Tube Carcinoma: A Review”, The Oncologist, 11 (8): 902-912 (2006).

L8.2. Goodman, MT., Shvetsov, YB., “Incidence of Ovarian, Peritoneal, and Fallopian Tube Carcinomas in the United States, 1995-2004”, Cancer Epidemiol Biomarkers Prev, 18 (1): 132-139 (2009).

L8.3. Bendavid, C., Pasquier, L., Watrin, T., Morcel, K., Lucas, J., et al. “Phenotypic variability of a 4q34 → qter inherited deletion: MRKH syndrome in the daughter, cardiac defect and Fallopian tube cancer in the mother”, European Journal of Medical Genetics, 50 (1): 66–72 (2007).

L8.4. Kietpeerakool, C., Suprasert, P., Srisomboon, J., Pantusart, A., “Primary Carcinoma of the Fallopian Tube: A Clinicopathologic Analysis of 27 Patients”, J Med Assoc Thai, 88 (10): 1338-43 (2005).

L8.5. Lin, CX., Shanling, WL., Xiao, X., Xuemei, Z., “Primary Fallopian Tube Carcinoma: A Clinical Analysis of 25 Patients”, Practical Journal of Obstetrics and Gynecology, 24 (5): (2008).

L8.6. Goswami, PK., Kerr-Wilson, R., McCarthy, K., “Cancer of the fallopian tube”, The Obstetrician & Gynaecologist, 8 (3): 147–152 (2006).

L8.7. Yane, Z., Bright, L., River, D., “One Case:Bilateral Calcific Carcinoma of Fallopian Tube”, Practical Journal of Radiology, 24 (8): (2008).

L8.8. Stein, RG., Diessner, J., Hönig, A., Wischhusen, J., Dietl, J., “Fallopian tube tumors: an overview”, Atlas of Genetics and Cytogenetics in Oncology and Haematology, 17 (11): 773-787 (2013).

L8.9. Ştefănescu, BI., Muscă, S., Ştefănescu, RM., Pricop, M., şi Farmacie, FD. M., “Primitive Fallopian Tube Carcinoma – About 3 Cases. Clinical Study”, Obstetrică-Ginecologie II, 10 (1): 140-145 (2011).

L8.10. Giri, SK., Nayak, B., “Malignancy and Fallopian Tubes: An In-depth Study”, in The Fallopian Tubes, ed., Tripathy, SN., 17: 149-154 (2013).

L8.11. Kalampokas, E., Kalampokas, T., Tourountous, I., “Primary fallopian tube carcinoma”, European Journal of Obstetrics & Gynecology and Reproductive Biology, 169 (2): 155–161 (2013).

L8.12. Shuzhi, D., Bin, S., “The original tubal adenocarcinoma metastatic carcinomas to spleen: 1 case report and literature review”, Journal of Hebei Medical University, 31 (2): (2010).

L8.13. Yuanjing, H., Fengxia, X., “Retroperitoneal lymphadenectomy influence on survival prognosis of primary Carcinoma of fallopian tube”, The Chinese Journal of practical Gynecology and obstetrics, 2010: 443-445 (2010).

L8.14. Jianqin, H., Li, W., Zhiling, Z., “Analysis of 22 cases with primary fallopian tube carcinoma diagnosis”, Chinese Journal of Cancer, 21 (8): (2011).

L8.15. Aiqin, R., Yu, L., “Fallopian tube carcinoma misdiagnosed as Carcinoma of the vagina: analysis of 1 cases”, Chinese Journal of Misdiagnosis, 24: (2011).

L8.16. Yue, L., Chun, H., Liping, Y., Jingjing, L., “Double uterus with endometrium and fallopian tubes of double tumor of 1 cases”, The journal of practical obstetrics and Gynecology, 25 (3): (2009).

L8.17. Bharti, MK., Chauhan, A., Sabharwal, R., “Primary Fallopian Tube Adenocarcinoma: A Case Report”, IJPSR, 2 (11): 3002-3005 (2011).

L9 (A25). M.M. Inal, Yildirim Y., Ertopcu K., Avci ME., Ozelmas I., Tinar S., “Effect of the subdermal contraceptive etonogestrel implant (Implanon) on biochemical and hormonal parameters (three years follow-up)”, Eur J Contracept Reprod Health Care, 13 (3): 238-42 (2008).

L9.1. Brito, MB., Ferriani, RA., Quintana, SM., Yazlle, MEHD., de Sá, MFS., Vieira, CS., “Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study”, Contraception, 80 (6): 519–526 (2009).

L9.2. Li, HWR., Wong, CYG., Yeung, WSB., Ho, PC., Ng, EHY., “Serum anti-müllerian hormone level is not altered in women using hormonal contraceptives”, Contraception, 83 (6): 582–585 (2011).

L9.3. Dilbaz, B., Ozdegirmenci, O., Caliskan, E., Dilbaz, S., Haberal, A., “Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels”, Contraception, 81 (6): 510–514 (2010).

L9.4. Arribas-Mir, L., Rueda-Lozano, D., Agrela-Cardona, M., Cedeño-Benavides, T., Olvera-Porcel, C., Bueno-Cavanillas, A., “Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain”, Contraception, 80 (5): 457–462 (2009).

L9.5. Brito, MB., Nobre, F., Vieira, CS., “Hormonal Contraception and Cardiovascular System”, Arq. Bras. Cardiol, 96 (4): 81-89 (2011).

L9.6. Oderich, CL., Wender, MCO., Lubianca, JN., Santos, LM., de Mello, GC., “Impact of etonogestrel-releasing implant and copper intrauterine device on carbohydrate metabolism: a comparative study”, Contraception, 85 (2): 173–176 (2012).

L9.7. Hohmann, H., “Examining the efficacy, safety, and patient acceptability of the etonogestrel implantable contraceptive”, Patient Prefer Adherence, 3: 205–211 (2009).

L9.8. Guazzelli, CAF., de Queiroz, FT., Barbieri, M., Barreiros, FA., Torloni, MR., Araujo, FF., “Metabolic effects of contraceptive implants in adolescents”, Contraception, 84 (4): 409–412 (2011).

L9.9. Zal, F., Mostafavi-Pour, Z., Amini, F., Heidari, A., “Effect of vitamin E and C supplements on lipid peroxidation and GSH-dependent antioxidant enzyme status in the blood of women consuming oral contraceptives”, Contraception, 86 (1): 62–66 (2012).

L9.10. Oderich, CL., “Estudo comparativo do Implante Subdérmico de Etonogestrel e do DIU de Cobre no Metabolismo dos Carboidratos”, PhD Thesis, Universidade Federal do Rio Grande do Sul, (2010).

L9.11. Jin-jin, L., Xin-yan, L., “The Clinical Performance of Single Rod Etonogestrel Implant”, International journal of reproductive health/family planning, 4: (2013).

L9.12. Bruni, V., Seravalli, V., Scarselli, G., “Contraccezione ormonale e rischio cardiovascolare”, SIC Donna news, 5 (2): 4-30 (2012).

L9.13. Brito, MB., Ferriani, RA., Quintana, SM., de sá, MFS., Vieira, CS., “Absence of adverse hepatic or renal effects with the etonogestrel-releasing contraceptive implant inserted immediately postpartum”, Open Access Journal of Contraception, 1: 127–133 (2010).

L9.14. Milica, B., Milica, M., “Hormonska kontracepcija - prednosti i zablude”, Medicinski Podmladak, 60 (1-2): 133-138 (2009).

L9.15. Hedderson, M., “Contraception Before and After GDM”, Gestational Diabetes During and After Pregnancy, 21: 317-329 (2010).

L10 (A26). Yildirim Y., Gultekin E., Avci ME., M.M. Inal, Yunus S., Tinar S., “Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer”, Int J Gynecol Cancer, 18 (2): 223-7 (2008).

L10.1. Zhang, Y., Shi, J., Li, Y., Wei, L., “Cardiomyocyte death in doxorubicin-induced cardiotoxicity”, Archivum Immunologiae et Therapiae Experimentalis, 57 (6): 435-445 (2009).

L10.2. Fjällskog, MLH., Janson, ET., Falkmer, UG., Vatn, MH., Öberg, KE., Eriksson, BK., “Treatment with Combined Streptozotocin and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic Tumors”, Neuroendocrinology, 88: 53–58 (2008).

L10.3. Paoli, EE., Kruse, DE., Seo, JW., Zhang, H., Kheirolomoom, A., et al. “An optical and microPET assessment of thermally-sensitive liposome biodistribution in the Met-1 tumor model: Importance of formulation”, Journal of Controlled Release, 143 (1): 13–22 (2010).

L10.4. Duggan, ST., Keating, GM., “Pegylated Liposomal Doxorubicin”, Drugs, 71 (18): 2531-2558 (2011).

L10.5. Strother, R., Matei, D., “Pegylated liposomal doxorubicin in ovarian cancer”, Ther Clin Risk Manag, 5: 639–650 (2009).

L10.6. Steer, CB., “Chemotherapy for Ovarian Cancer in the Older Adult”, Current Treatment Options in Oncology, 10 (3-4): 159-170 (2009).

L10.7. Maradia, K., Guglin, M., “Pharmacologic prevention of anthracycline-induced cardiomyopathy”, Cardiol Rev, 17 (5): 243-52 (2009).

L10.8. Yiwei, Z., Yuanjian, L., “Recent insights into doxorubicin-induced cardiomyocyte death”, International Journal of Clinical and Pathological Science, 2: (2011).

L10.9. Henderson, IC., “Development of PEGylated Liposomes, in Drug Delivery in Oncology: From Basic Research to Cancer Therapy (eds F. Kratz, P. Senter and H. Steinhagen)”, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany (2011).


Download 248.43 Kb.

Share with your friends:
1   2   3




The database is protected by copyright ©ininet.org 2020
send message

    Main page